Anti-Human CD56 (NCAM) (Clone ERIC-1) – Purified in vivo GOLD™ Functional Grade
Pricing & Details
Human Retinoblastoma tumor
1.0 - 5.0 mg/ml
≤ 1.0 EU/mg as determined by the LAL method
>95% by SDS-PAGE and HPLC
This antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.
Storage and Handling
This antibody is stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Next Day 2-8°C
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Mouse Anti-Human CD56 (Clone ERIC-1) recognizes Human CD56. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype. Anti-Human CD56 recognizes the (Mr 180, 145, 125 kDa) isoforms of the human neural cell adhesion molecule (NCAM).1
The CD56 (NCAM) antigen is expressed on most neuroectodermal derived cell lines, tissues, and tumors. NCAM is also known to be expressed on some mesodermally derived tissues such as muscle1 and on natural killer (NK) lymphocytes. The binding of ERIC-1 to both normal and neoplastic tissue is lost when tissues are conventionally fixed in formalin and embedded in paraffin. The epitope was preserved when exposed to dehydrating fixatives such as cold acetone (-20EC) for 5 min. CD56 is present on 10-25% of peripheral blood lymphocytes.
Anti-Human CD56 can be used in studies of the neural cell adhesion molecule. This antibody may also be used to study isoforms of NCAM expressed on different tumor types. Anti-CD56 (clone ERIC-1) works well in western blot for analysis of isoforms expressed. Anti-CD56 did not react with any of the leukemias or lymphomas tested.1
NCBI Gene Bank ID
References & Citations
1. Bourne, K. et al. (1991) J. of Neuro-Oncology 10:111